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Abstract
Background: Coffee consumption has been shown to be associated with cancer of various sites in
epidemiological studies. However, there is no comprehensive overview of the substantial body of epidemiologic
evidence.
Methods: We searched MEDLINE, EMBASE, Science Citation Index Expanded and bibliographies of retrieved articles.
Prospective cohort studies were included if they reported relative risks (RRs) and corresponding 95% confidence
intervals (CIs) of various cancers with respect to frequency of coffee intake. We did random-effects meta-analyses
and meta-regressions of study-specific incremental estimates to determine the risk of cancer associated with 1
cup/day increment of coffee consumption.
Results: 59 studies, consisting of 40 independent cohorts, met the inclusion criteria. Compared with individuals
who did not or seldom drink coffee per day, the pooled RR of cancer was 0.87 (95% CI, 0.82-0.92) for regular coffee
drinkers, 0.89 (0.84-0.93) for low to moderate coffee drinkers, and 0.82 (0.74-0.89) for high drinkers. Overall, an
increase in consumption of 1 cup of coffee per day was associated with a 3% reduced risk of cancers (RR, 0.97;
95% CI, 0.96-0.98). In subgroup analyses, we noted that, coffee drinking was associated with a reduced risk of
bladder, breast, buccal and pharyngeal, colorectal, endometrial, esophageal, hepatocellular, leukemic, pancreatic,
and prostate cancers.
Conclusions: Findings from this meta-analysis suggest that coffee consumption may reduce the total cancer
incidence and it also has an inverse association with some type of cancers.
Background
Coffee is one of the most widely consumed beverages in
the world, with a yearly world average consumption of
1.1 kg per capita, which reaches 4.5 kg in industrialized
countries[1]. More recently, coffee consumption has
been associated with reductions in the risk of several
chronic diseases, including type 2 diabetes mellitus, Par-
kinson’s disease and hepatocellular disease[2-4]. Among
them, the relationship between coffee drinking and can-
cer risk holds great interest.
Roasted coffee is a complex mixture of more than a
thousand chemicals. Many constituents in it could
potentially alter cancer risk through several biological
mechanisms. Coffee is the major source of caffeine
which has been reported to both stimulate and suppress
tumors, depending upon the species and the phase of
administration[5]. There are two specific diterpenes in
coffee, cafestol and kahweal, which produce biological
effects compatible with anticarcinogenic properties,
including the induction of phase II enzymes involved in
carcinogen detoxification,[6] specific inhibition of the
activity of phase I enzyme responsible for carcinogen
activation and stimulation of intracellular antioxidant
defence mechanisms[7]. Polyphenols are an important
ingredient in coffee, such as lignan phytoestrogens and
flavonoids and polyphenols are found to exhibit anticar-
cinogenic properties in several studies[8]. Caffeic acid
has the ability to inhibit DNA methylation in cultured
human cancer cells and is associated with inactivation
of various pathways involved in the tumorigenic process,
including cell cycle regulation, inflammatory and stress
response and apoptosis[9]. Coffee is also a major source
of the chlorogenic acid that contributes to its antioxi-
dant effect. Intake of chlorogenic acid has been shown
to reduce glucose concentrations in rats and intake of
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increases insulin sensitivity[10]. Chronic hyperinsuline-
mia and insulin resistance are confirmed markers of
high risk for some cancer sites[11].
Over the last 4 decades, a number of epidemiologic
studies (over 500 papers) have estimated the associations
between coffee consumption and cancer occurrence at
various sites. However, their results were inconsistent.
In 2007, the World Cancer Research Fund (WCRF) con-
ducted a comprehensive analysis of diet and cancer,
using a more standardized approach to review the evi-
dence. This report addressed the significant relation-
ships between coffee and risk of pancreatic and kidney
cancer[5]. In fact, epidemiologic studies have been pub-
lished relating coffee intak et oc a n c e r so f1 1d i f f e r e n t
organ sites. Data from case-control studies may be sub-
ject to recall bias with respect to coffee consumption
and selection bias with respect to the control group.
Additional prospective cohort studies excluding those
biases would be more useful to see coffee-cancer asso-
ciations. We therefore systematically reviewed and per-
formed a meta-analysis of prospective cohort studies to
quantitatively assess the association between coffee
intake and cancer risk in human. Because of the high
consumption of coffee, even small effects on cancer
occurrence in persons could have a large impact on
public health.
Methods
Literature search
We searched the electronic databases MEDLINE (1966 to
March, 2010), EMBASE (1985 to March, 2010), and
Science Citation Index Expanded (1945 to March, 2010),
using the Medical Subject Heading (MeSH) term coffee
combined with cancer or neoplasm or carcinoma.F u r t h e r -
more, we reviewed reference lists of retrieved articles to
search for more studies. Only those that were published as
full-length articles and in English were considered.
Inclusion and exclusion criteria
For inclusion, studies had to fulfil the following criteria:
have a prospective cohort design; report relative risks or
hazard ratios and their corresponding 95% CIs (or data
to calculate them) of cancer relating to every category of
coffee intake; and provide the frequency of coffee con-
sumption. Studies were excluded if: case-control design
was used; mixed beverage was reported, in which the
effect of coffee could not be separated; only surrogate
nutrients of coffee were reported; no categories of coffee
intake were reported that could not allow for adequate
classification of intake. If multiple published reports
from a same study cohort were available, we included
only the one with the most detailed information for
both outcome and coffee consumption.
Data extraction
Data were extracted independently by two investigators
(Yu and Bao) according to the meta-analysis of observa-
tion studies in epidemiology (MOOSE) guidelines,[12]
and discrepancies were resolved by discussion with a
third investigator (Zou). For each study, the following
information was extracted: first author’s last name; year
of publication; country of origin; follow-up period; num-
ber of subjects and cases; age at baseline; cancer sites;
category amounts of coffee intake; outcome assessment;
relative risks or hazard ratios of cancer and correspond-
ing 95% CIs for every category of coffee intake; and cov-
ariates adjusted in the statistical analysis.
Statistical analysis
The measures of interest were the RR and the corre-
sponding 95% CIs for the included cohort studies.
When RRs were not available in the published article,
they were computed from the exposure distributions.
Because various studies used different measurement
units for coffee consumption, we converted these into
cups per day as a standard measure. If coffee consump-
tion was indicated in milliliters, we assumed 125 mL as
approximately equivalent to 1 cup.
We computed the summary RR for coffee drinkers
versus nondrinkers and for different levels of consump-
tion by giving each study-specific RR a weight that was
proportional to its precision (ie, the inverse of the var-
iance derived, when necessary, from the reported 95%
CIs). To estimate the summary RR for various levels of
coffee consumption, we first calculated the study-speci-
fic estimate separately for low to moderate consumption
and high consumption. For various cancer sites, we per-
formed stratified analysis on cancer types which had
more than two cohorts.
Statistical heterogeneity among studies was estimated
using Q and I
2 statistics. For the Q statistic, heterogene-
ity was considered present for P < 0.1. We pooled the
study-specific estimates using both the fixed effect
model and the random effect model proposed by DerSi-
monian and Laird; when a significant heterogeneity was
found, the random effect model results were presented.
A sensitivity analysis was also conducted, in which 1
study at a time was removed and the others analyzed to
estimate whether the results could have been affected
markedly by a single study.
For dose-response analysis, we used the method pro-
posed by Greenland and Longnecker[13] to estimate
study-specific slopes from the correlated natural loga-
rithm of the RR across categories of coffee consumption,
assigning to each class the dose corresponding to the
midpoint of upper and lower boundaries. The highest,
open-ended category was assumed to have the same
amplitude of consumption as the preceding category
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day increment of coffee consumption was obtained by
pooling the study-specific slopes, using the inverse of
the corresponding variances as weights.
Finally, publication bias was evaluated through funnel
plot visual analysis and with the Begg’sa n dE g g e r ’s
tests. P < 0.05 was considered statistically significant. All
statistical analyses were performed with STATA (version
9.0; Stata Corp, College Station, TX).
Results
Using the predefined search strategy, we identified 59
publications, 40 prospective cohort studies, (Figure 1)
including 2,179,126 participants and 34,177 incident
cases of cancer with an average follow-up of 14.3 years,
which were eligible for inclusion in the meta-analysis
[15-73]. The characteristics of the included studies are
summarized in Additional file: 1. Initial agreement
between the two reviewers on whether a study was eligi-
ble for inclusion occurred in 207/221 manuscripts
(93.7%;  = 0.874). Of the 40 cohorts included in the
meta-analysis, 13 were conducted in Europe (Norway,
Denmark, Sweden, France, Finland, and Netherlands),
15 in North America (Canada and the United States),
and 12 in Asia (Japan and Singapore).
The estimated RRs of various cancer sites for coffee
drinkers vs non/lowest drinkers was 0.87 (95% CI, 0.82-
0.92). There was significant heterogeneity across the stu-
dies (Q = 178.1, P <0 . 0 0 1 ,I
2 = 78.1%). The summary
RR was 0.89 (95% CI, 0.84-0.93) for low to moderate
coffee consumption, with a significant heterogeneity
between studies (Q = 95.78, P < 0.001, I
2 = 61.4%). That
for high consumption of coffee was 0.82 (95% CI, 0.74-
0.89), also with a significant heterogeneity between stu-
dies (Q = 114.71, P < 0.001, I
2 = 67.7%).
Various sources of heterogeneity likely exist due to
international differences in coffee consumption (e.g.,
coffee type, serving size, or brewing method) in this ana-
lysis. To examine the magnitude of the combined RR in
each stratum and its respective test of heterogeneity, we
conducted subgroup analyses by gender, cancer sites,
and geographic regions. The summary RR was 0.88
(95% CI, 0.78-0.98) for men and 0.87 (95% CI, 0.82-
0.93) for women combining all studies. There was a sig-
nificant heterogeneity for men (Q = 118.27, P < 0.001, I
2
= 84.8%) and for women (Q = 90.61, P < 0.001, I
2 =
75.7%).
When stratified by cancer sites, we noted that, coffee
consumption was inversely associated with bladder (RR
0.83 (95% CI, 0.73-0.94)) (Figure 2), breast 0.94 (0.91-
0.98) (Figure 3), buccal and pharyngeal 0.49 (0.29-0.70),
colorectal 0.89 (0.80-0.97) (Figure 4), endometrial 0.74
(0.63-0.84) (Figure 5), esophageal 0.55 (0.37-0.74), hepa-
tocellular 0.54 (0.46-0.61) (Figure 6), leukemic 0.64
(0.51-0.77), pancreatic 0.82 (0.69-0.95) (Figure 7), and
prostate 0.79 (0.61-0.98) (Figure 8) cancers. There
appeared to be no association with stomach, lung, non-
melanoma, ovarian, or kidney cancer. The summary RR
for an increment of 1 cup of coffee per day was 0.97
(95% CI, 0.96-0.98) for all studies combined. The pooled
RR for various cancer sites and incremental estimates
for 1 cup/day increment of coffee consumption
and their heterogeneity are listed in Additional file 2:
Table S2.
Associations were also similar in studies from North
America, Europe, and the Asia-Pacific region. The RR
was 0.92 (95% CI, 0.86-0.98) when considering 15 stu-
dies conducted in North America, 0.85 (95% CI, 0.72-
0.98) for 13 studies from Europe and 0.82 (95% CI,
0.74-0.90) for 12 Asian studies. No significant differ-
ences by sex and cancer-site were found.
There was no indication of publication bias from
either visualization of the funnel plot or Egger’s( P=
0.793) and Begg’s( P=0 .981) (Figure 9) tests. A sensitiv-
ity analysis, in which 1 study was removed at a time,
was performed to evaluate the stability of the results.
This analysis confirmed the stability of our results.
Discussion
Coffee can potentially impact the etiology of cancer of
various sites along multiple pathways, ranging from car-
cinogenesis to cellular apoptosis. For most cancer sites,
there is a significant amount of evidence showing no
detrimental effect of consumption of up to 6 cups of
coffee per day in relation to cancer occurrence. Through
the meta-analysis of cohort studies, we found that com-
pared with individuals who did not or seldom drink cof-
fee per day, regular coffee drinkers had lower cancer
o c c u r r e n c e ,p a r t i c u l a r l yf o rh i g hd r i n k e r s .O v e r a l l ,a n
increase in consumption of 1 cup of coffee per day was
associated with a 3% reduced risk of cancers. The
Figure 1 Flow diagram of search strategy and study selection.
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might reduce cancer occurrence in humans.
A significant amount of literature exists on relation-
ships between coffee consumption and human cancer
occurrence at 11 organ sites. It has been confirmed that
coffee consumption is associated with a reduced risk of
hepatocellular, kidney, and to a lesser extent, premeno-
pausal breast and colorectal cancers, while it is unre-
lated to prostate, pancreas and ovary cancers.n subgroup
analyses, we note that, for bladder, breast, buccal and
pharyngeal, colorectal, endometrial, esophageal, hepato-
cellular, leukemic, pancreatic, and prostate cancers,
there appears to be an inverse association.
Over the past two decades, many studies have been
carried out after the early warning in the early 1980 s
that coffee consumption was related to pancreatic can-
cer risk. These investigations yield inconsistent results.
Since the WCRF report, Luo et al[59] studied the asso-
ciation between the drinking coffee and the risk of
pancreatic cancer in a large population-based cohort
study in Japan and concluded there was no increased
risk of pancreatic cancer with coffee intake. A reduced
risk was apparent among men who drank at least 3 cups
of coffee per day. After a pooled analysis of 14 cohort
studies, we found that coffee consumption had a signifi-
cantly inverse association with the risk of pancreatic
cancer.
Among investigations that have addressed the associa-
tion between coffee consumption and the risk of kidney
cancer, a pooled analysis of 13 cohort studies found
that, coffee consumption was associated, but not signifi-
cantly, with a lower risk of kidney cancer[74]. Among
the participants in the Nurses’ Health Study and the
Health Professionals Follow up Study, no association
was seen between coffee intakes and risk of kidney can-
cer [63]. However, this conclusion is not confirmed by
our results. There was a protective effect on men who
drink coffee and for high coffee drinkers. Coffee
Figure 2 Summary RRs of bladder cancer for coffee drinkers versus non/lowest drinkers from included studies. Squares represent study-
specific relative risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal lines
represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs.
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caffeine has a diuretic effect by blocking anti-diuretic
hormone and antioxidants in coffee alleviate oxidative
damage to DNA, proteins and other molecules. More-
over, coffee consumption may reduce the risk of kidney
cancer by improving insulin sensitivity[75].
Colorectal cancer is one of the most common cancers
worldwide. It has been suggested that coffee is a
protective factor against colorectal cancer through its
carcinogenic constituents, cafestol and kahweal and its
ability to induce excretion of bile acids and neutral ster-
ols into the colon[76]. Moreover, coffee might decrease
colorectal cancer risk by increasing large bowel mobility
in the rectosigmoid region, while caffeine has been
shown to inhibit colon cancer cell growth[77]. A meta-
analysis of prospective cohort studies on colorectal can-
cer and coffee consumption was completed and pub-
lished in 2009[78]. The result of it showed no significant
effect of coffee consumption on colorectal cancer risk.
However, in our meta-analysis, 15 cohorts were identi-
fied from Japan, Norway, Finland, Singapore, Sweden,
and the United States. We found that coffee consump-
tion had an inverse association with the risk of colorec-
tal cancer.
Preliminary results from the Nurses Health Study
suggested a weak inverse association between caffeine
intake and the risk of breast cancer[44]. A Norwegian
cohort of 14,593 women who drank ≥5c u p so fc o f f e e
per day experienced a statistically significant 50%
decrease in breast cancer risk compared to those who
drank ≤2 cups[79]. A meta-analysis of 9 cohort and 9
case-control studies found a borderline significant
influence of highest coffee consumption on the risk of
breast cancer. The results of our meta-analysis also
confirmed the former conclusion and showed coffee
drinking had an inverse association with breast cancer.
We also observed a reduction of 26% in the risk of
endometrial cancer among coffee drinkers, compared
with nondrinkers, and of >30% among heavy coffee
drinkers.
In addition, higher intake of caffeine and caffeine-con-
taining beverages has been positively associated with sex
hormone binding globulin and inversely associated with
bioavailable testosterone[80]. These hormonal changes
may favorably influence breast or endometrial cancer
risk. Coffee consumption was also shown to be asso-
ciated with increased ratio of plasma 2-hydroxyestrone
to 16-alphahydroxyestrone, a predictor of lower breast
cancer risk[81].
A meta-analysis, including 6 case-control and 4
cohort studies reported a statistically significant 41%
reduction in the hepatocellular cancer risk among cof-
fee drinkers compared with never drinkers, with simi-
lar results from case-control and prospective studies
[82]. Another meta-analysis of 4 cohort and 5 case-
control studies found that an increased coffee con-
sumption is associated with a reduced risk of hepato-
cellular cancer, both among individuals with and
without a history of hepatocellular disease[83]. Our
meta-analysis including 5 cohort studies also suggested
a significant inverse relation between coffee intake and
hepatocellular cancer.
Figure 3 Summary RRs of breast cancer for low to moderate
coffee drinkers versus non/lowest drinkers from included
studies. Squares represent study-specific relative risk estimates (size
of the square reflects the study-specific statistical weight, that is, the
inverse of the variance); horizontal lines represent 95% CIs; diamonds
represent summary relative risk estimates with corresponding 95% CIs.
Figure 4 Summary RRs of colorectal cancer for high coffee
drinkers versus non/lowest drinkers from included studies.
Squares represent study-specific relative risk estimates (size of the
square reflects the study-specific statistical weight, that is, the
inverse of the variance); horizontal lines represent 95% CIs; diamonds
represent summary relative risk estimates with corresponding 95%
CIs.
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Page 5 of 11Figure 5 Summary RRs of endometrial cancer for high coffee drinkers versus non/lowest drinkers from included studies. Squares
represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance);
horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs.
Figure 6 Summary RRs of hepatocellular cancer for high coffee drinkers versus non/lowest drinkers from included studies. Squares
represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance);
horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs.
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cellular cancer is biologically plausible. Coffee contains
large amounts of antioxidants, such as chlorogenic
acids, and experimental studies in animals have demon-
strated an inhibitory effect of coffee and chlorogenic
acids on hepatocellular carcinogenesis[84]. In one ani-
mal study, caffeine levels of coffee extracts were inver-
sely related to hepatocellular injury[85]. A population-
based case-control study in the United States showed
that higher intake of coffee, and especially caffeine, was
associated with a lower prevalence of abnormal alanine
aminotransferase activity[86]. In addition, some studies
have reported an inverse association between coffee
consumption and risk of hepatocellular cirrhosis, which
is strongly related to HCC[87].
Coffee consumption and cancer of the urinary track
was systematically reviewed in 2001[88]. We incorpo-
rated data on adjusted summary RRs from 9 cohort
studies and found coffee to be inversely associated with
bladder cancer in men, whereas the trend was not seen
in women. The Lutheran Brotherhood Cohort study
found coffee consumption unrelated to prostate cancer
risk[60]. But we found that the summary RR of prostate
cancer was 0.79 for coffee drinkers vs nondrinkers.
Some limitations of this meta-analysis should be
acknowledged. First, as in all observational studies of diet
and disease, the possibility of bias and confounding can
n o tb ee x c l u d e d( f o rs o m es u b j e c t sm a yh a v em o d i f i e d
their coffee drinking habit after the baseline assessment).
However, cohort studies, which are less susceptible to
bias because of the prospective design, also showed an
inverse association between coffee consumption and risk
of cancer, suggesting that the finding is not likely attribu-
table to recall and selection bias. Individual studies may
have failed to adjust for potential known or unknown
confounders. Second, our results are likely to be affected
Figure 7 Summary RRs of pancreatic cancer for high coffee drinkers versus non/lowest drinkers from included studies. Squares
represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance);
horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs.
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exposure is mostly assessed regarding the number of
cups of coffee consumed daily, weekly or monthly. How-
ever, most of the studies included in our meta-analysis
did not provide information on coffee type, serving size,
or brewing method. Serving sizes and brewing methods
for coffee can vary substantially within and between
c o u n t r i e s .T h es i z eo fs t a n d a r dc o f f e ec u p si sl a r g e ri n
the United States compared with that in Europe or Japan,
and the difference in the strength of coffee brew may
compensate for the different serving size between coun-
tries[89]. Third, we extracted the risk estimates that
reflected the greatest degree of the control potential con-
founders, the results based on the adjustment for differ-
ent confounders were probably different from those
based on standardized adjustments. Finally, only pub-
lished studies were included in our meta-analysis. There-
fore, publication bias may have occurred although no
publication bias was indicated from both visualization of
the funnel plot and Egger’s test.
Figure 8 Summary RRs of prostate cancer for high coffee drinkers versus non/lowest drinkers from included studies. Squares represent
study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal
lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs.
Figure 9 Publication bias in the studies.B e g g ’s funnel plot
indicating no publication bias in the studies included in this meta-
analysis. No indication of publication bias was noted from both
visualization of funnel plot and Egger’s test.
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All in all, our meta-analysis including 40 prospective
cohort studies confirmed that coffee drinking have no
harmful effect. Instead, coffee consumption is inversely
associated with the risk of bladder, breast, buccal cavity
and pharynx, colorectum, endometrium, esophagus,
hepatocellular, leukemia, pancreas, and prostate cancers.
Additional material
Additional file 1: Table S1. Summary characteristics of studies included
in the meta-analysis.
Additional file 2: Table S2. The summary RR for various cancer sites or
different geographic regions and incremental estimates for 1 cup/day
increment of coffee consumption.
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